Company:  LUCID DIAGNOSTICS INC. (LUCD)
Form Type:  S-1
Filing Date:  9/22/2021 
CIK:  0001799011 
Address:  ONE GRAND CENTRAL PLACE
SUITE 4600
 
City, State, Zip:  NEW YORK, New York 10165 
Telephone:  212-949-4319 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$7.10  
Change: 
-0.04 (-0.56%)  
Trade Time: 
Dec 08  
Market Cap: 
$261.34M
Trade LUCD now with 

© 2021  
Description of Business
We are a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma (EAC). We believe that our lead products, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell Collection Device in a brief noninvasive office procedure, constitute the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent EAC deaths, through early detection of esophageal precancer and cancer in at-risk GERD patients. We believe EsoGuard could have as great an impact in preventing EAC deaths as widespread Pap test screening has had in preventing cervical cancer deaths.
Register and access this filing in:     
  FORM S-1
    CALCULATION OF REGISTRATION FEE
    PRELIMINARY PROSPECTUS Subject to Completion September 22, 2021
    TABLE OF CONTENTS
    ABOUT THIS PROSPECTUS
    THE OFFERING
    SUMMARY FINANCIAL DATA
    RISK FACTORS
    CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
    USE OF PROCEEDS
    CAPITALIZATION
    DILUTION
      BENEFICIAL OWNERS
    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION ...
      Liquidity and Capital Resources
    BUSINESS
      Competition
      Employees
      Legal Proceedings
    MANAGEMENT
      NAME AND TITLE
    Conflicts of Interest
    Director Compensation
    EXECUTIVE COMPENSATION
      Stock Subject to the 2018 Equity Plan
    PRINCIPAL STOCKHOLDERS
      BENEFICIAL OWNERS
    CERTAIN TRANSACTIONS
    Related Party Transactions
    DESCRIPTION OF COMMON STOCK
    Our Transfer Agent
    SHARES ELIGIBLE FOR FUTURE SALE
    UNDERWRITING
    LEGAL MATTERS
    EXPERTS
    WHERE YOU CAN FIND ADDITIONAL INFORMATION
    INDEX TO FINANCIAL STATEMENTS
      STOCKHOLDERS EQUITY
      NOTES TO UNAUDITED CONDENSED FINANCIAL STATEMENTS
    Note 1 - Summary Description of the Company and Financial ...
    Note 1 - Summary Description of the Company and Financial ...
      OPTIONS
      REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
    Note 1 - Summary Description of the Company and Financial ...
    Note 1 - Summary Description of the Company and Financial ...
    PART II
      Item 13. Other Expenses of Issuance and Distribution.
      Item 14. Indemnification of Directors and Officers.
      Item 15. Recent Sales of Unregistered Securities.
      Item 16. Exhibits and Financial Statement Schedules.
      Item 17. Undertakings.
    SIGNATURES
    POWER OF ATTORNEY
  EXHIBIT 23.1
    Independent Registered Public Accounting Firm's Consent
  EXHIBIT 99.1